The use of anti-venom is the most reliable treatment for snakebite. However, snake venom differs across species and within species, depending on factors like age, environment, diet, and season. Therefore, anti-venoms must be snake-specific as well as region-specific to be effective.
Researchers have identified more opportunities to improve the therapies and anti-venoms suitable to save lives. Lately, new biotechnological tools have been applied with the aim of improving the efficacy, safety, and affordability of anti-venoms. Within the avenues explored, novel immunization strategies using synthetic peptide epitopes, recombinant toxins, or DNA strings as immunogens have demonstrated potential for generating anti-venoms with high therapeutic antibody titers and broad neutralizing capacity. Furthermore, the significant benefits of innovative immunizations approaches are that they are often compatible with existing manufacturing setups, further enhancing innovations in the global anti-venom market.
Got questions about your regional growth of
Just drop us a line or call on +1 646 480 7505
Impact of COVID-19 on the Global Anti-Venom Market
The outbreak of the global pandemic COVID-19 has forced many industries to halt productions across the globe. It has led to several disruptions in the supply chain, which has further contributed to the lack of global availability of anti-venom. Health facilities often don't have the capacity for rehabilitative care, even less so in times of COVID-19. The Health Action International has stated various community measures to prevent snakebites and pressure on health systems.
Global Anti-Venom Market Segmentation
By Product Type
By Mode of Action
By End User
" Crucial Insights The Report Provides:"
* Known and Unknown Adjacencies Influencing the Growth of Market
* Explorable Revenue Sources
* Customer Behaviour Analysis
* Target Partners
* Customized Geographical Data Based on Customers as well as Competitors
* Analysis of Market Size and CAGR between the Forecast PeriodsView Full Report Buy This Report Now